display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - L2 - PDL1 negative
immune chekpoint inhibitors
Immune checkpoint association
durvalumab plus tremelimumab CONDOR ... CONDOR ...

Study type: